This study investigates the time course of change in calcium in the blood after a pregnant subject takes an oral dose of calcium carbonate (commonly marketed as "Tums"). This information is important for trials investigating whether calcium can reduce postpartum hemorrhage, bleeding after delivery.

Start Date01 Jan 2025

Sponsor / Collaborator

Stanford University

NCT06580782

/ RecruitingPhase 4IIT

Calcium Carbonate to Augment Labor Contractions

The investigators think that calcium carbonate can act as an assistive medication to improve contractions during labor.

Start Date18 Nov 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT06352775

/ Active, not recruitingNot ApplicableIIT

The Effect of Calcium Carbonate on Labor Induction: A Pilot Study

The investigators aim to evaluate the safety and efficacy of administering calcium carbonate to laboring participants undergoing labor inductions. The investigators hypothesize that calcium carbonate is a low-risk preventative measure to decrease oxytocin induction time and dosage, decrease the rate of labor dystocia, decrease the rate of cesarean deliveries, and demonstrate no differences in maternal or neonatal safety outcomes.

Start Date01 Jun 2024

Sponsor / Collaborator

Wake Forest School of Medicine

100 Clinical Results associated with Calcium carbonate

100 Translational Medicine associated with Calcium carbonate

100 Patents (Medical) associated with Calcium carbonate

56,737

Literatures (Medical) associated with Calcium carbonate

01 Jul 2026·AMERICAN JOURNAL OF CLINICAL NUTRITION

Effects of a 1-year calcium-enriched permeate supplement on bone health in postmenopausal females: The RENEW randomized controlled intervention trial

Article

Author: Lemay, Danielle G ; Tetens, Inge ; Bertram, Hanne C ; Rasmussen, Sidse Ii ; Andersen, Henrik J ; Nielsen, Dennis S ; Hitz, Mette F ; Kisi, Sadime B ; Cramon, Mai Ø ; Petersen, Caroline F ; Parlesak, Alexandr

BACKGROUND:

Osteoporosis is a common age-related skeletal disorder, especially in postmenopausal females, underscoring the need for effective nutritional strategies to preserve bone health. Calcium-enriched permeate (CP) and inulin may enhance absorption and bone mineral density (BMD).

OBJECTIVES:

To assess the effects of daily supplementation of calcium-enriched permeate, with inulin (CP-Inu) or without inulin, and calcium carbonate (CC) on bone turnover markers and BMD in vitamin D-sufficient postmenopausal females.

METHODS:

In this 12-mo randomized, double-blind, multi-center trial, postmenopausal females were allocated to receive daily either a maltodextrin as placebo (P), 800 mg calcium as CC, CP, or CP-Inu split into 2 doses. All received 20 μg vitamin D per day. Primary outcome was C-terminal telopeptides of type I collagen; secondary outcomes were procollagen type I N-terminal propeptide and BMD. Linear mixed-effects models were used to assess fixed and random effects. adjusted for multiple outcomes.

RESULTS:

Of 417 participants (56.0 ± 4.2 y; BMI 25.5 ± 3.8), 316 (76%) completed the study with a mean 89% overall compliance. C-terminal telopeptides of type I collagen remained unchanged from baseline to 12 mo in the P group, whereas all intervention groups showed significant reductions compared with P (μg/L) [CC: β = -0.137; 95% confidence interval (CI): -0.193, -0.081, P = 2.59 × 10^-6; CP: β: = -0.150; 95% CI: -0.208, -0.093, P = 1.62 × 10^-6; CP-Inu β: = -0.149; 95% CI: -0.207, -0.090, P = 1.96 × 10^-6]. Compared with P, procollagen type I N-terminal propeptide was significantly reduced in all intervention groups. By month 12, spine BMD (grams per square centimeter) was higher with CC: β = 0.0158, (0.0066, 0.0251), P = 0.0009; CP-Inu, β = 0.0142, (0.0046, 0.0238), P = 0.0040, and femoral neck BMD was higher with CP, β = 0.0116, (0.0042, 0.0190), P = 0.0022. No additional effects were observed in the CP-Inu group.

CONCLUSIONS:

Daily supplementation of 800 mg calcium in 2 doses from CP suppresses bone turnover markers and maintains BMD similarly to CC in vitamin D-sufficient postmenopausal females. Inulin provides no additional advantage. This trial was registered at clinicaltrials.gov as NCT04836637.

01 Jun 2026·American Journal of Obstetrics & Gynecology MFM

Oral calcium carbonate as an adjunct to oxytocin infusion for labor induction: a randomized controlled pilot study on feasibility and acceptability

Article

Author: Garcia, Mirely ; Boers, Julia Romina M ; Voegtline, Kristin ; Sanchez, Ester ; Son, Moeun

BACKGROUND:

Calcium carbonate supplementation may offer a simple, low-cost adjunctive benefit to synthetic oxytocin that could enhance the effectiveness of medical labor induction, reduce associated risks, and improve outcomes for both mother and baby. However, its potential role as an adjunct uterotonic remains understudied.

OBJECTIVE:

This study aimed to assess the feasibility and acceptability of conducting a large randomized controlled trial evaluating the effect of coadministering oral calcium carbonate with synthetic oxytocin infusion during labor induction on labor and delivery outcomes.

STUDY DESIGN:

This randomized, controlled, open-label pilot study included nulliparous women with a singleton pregnancy at ≥36 weeks of gestation, a healthy fetus in cephalic presentation, and a planned induction or augmentation of labor with synthetic oxytocin (Pitocin). Patients were excluded if their fetal monitoring showed recurrent fetal heart rate decelerations or tachysystole in the 30 minutes prior, if they had a planned cesarean delivery, a known contraindication to calcium carbonate, or were receiving treatment with calcium channel blockers or magnesium. Participants were randomized in a 1:1 ratio to receive either synthetic oxytocin alone (control) or oral calcium carbonate coadministered with oxytocin (intervention). The intervention group was assigned to receive 500 mg of calcium carbonate every 4 hours, starting at the initiation of oxytocin infusion. Labor characteristics and outcomes were recorded. The primary outcomes were feasibility and acceptability measures: recruitment, enrollment, and adherence rate to the study protocol.

RESULTS:

From November 18, 2024, to October 16, 2025, 182 patients were screened for study eligibility. Of these, 137 met eligibility criteria (75%), and 122 (89%) were approached by available research staff. A total of 59 patients (48% of those approached) consented, and 55 participants were randomized: 26 were assigned to receive standard care oxytocin infusion, and 29 were assigned to receive oral carbonate in combination with oxytocin infusion. One patient randomized to the control group underwent cesarean delivery for nonreassuring fetal status prior to oxytocin administration, and one patient randomized to calcium carbonate delivered prior to intervention start; both patients were therefore excluded from analysis. All other participants adhered to their assigned intervention. Among those in the calcium carbonate group, the median number of tablets administered calcium carbonate was 3 tablets (range 2-4). Although not powered for clinical outcomes, exploratory analyses suggest trends toward a higher frequency of spontaneous vaginal delivery, shorter time to delivery, and lower oxytocin exposure, including shorter duration and lower maximum dose, in the calcium carbonate group compared to the control group.

CONCLUSION:

Random allocation to standard care, oxytocin, or calcium carbonate in combination with oxytocin for labor induction was feasible and acceptable to patients and clinicians. El resumen está disponible en Español al final del artículo.

01 Jun 2026·SAUDI PHARMACEUTICAL JOURNAL

Formulation and optimization of gastroretentive tablets containing famotidine in combination with antacids: In vitro evaluations and stability studies

Article

Author: Radwan, Awwad A ; Alghaith, Adel F ; Aldosari, Azizah M ; Mahrous, Gamal M

Famotidine (FMD) is a histamine H₂-receptor antagonist frequently co-administered with antacids to accomplish synergistic effects. It exhibits a rapid onset of action, limited bioavailability, and a short half-life. Effervescent floating tablets (EFTs) are low-density gastroretentive formulations designed to overcome the limited bioavailability of drugs. This study aims to develop single-layer EFTs to provide sustained drug release and prolonged gastric residence time. The EFTs were formulated for FMD in combination with calcium carbonate and aluminum hydroxide as antacids using the direct compression technique. The study investigated the effects of varying ratios of guar gum, hydroxypropyl methylcellulose (HPMC), and polyvinylpyrrolidone (PVP) on parameters including hardness, friability, floating lag time, dissolution efficiency (DE), and cumulative drug release after 8 h. The optimized EFTs formulation was composed of 14.74% w/w guar gum, 7% w/w HPMC, and 15% w/w PVP. It demonstrated a hardness of 54.28 N, friability of 0.74%, a floating lag time of 40.69 min, a DE of 53.25%, and a cumulative drug release of 84.64%. The results closely aligned with the predicted values of 55.2 N, 0.72%, 32.12 min, 59.87%, and 87.8%, respectively. Furthermore, the optimized EFTs formulation remained stable under accelerated stability conditions for 6 months and provided sustained drug release compared with commercial tablets, which released their contents within 30 min.

News (Medical) associated with Calcium carbonate

26 Dec 2025

·www.einpresswire.com

A Chiropractor’s Perspective on Structural and Neurological Factors in Hiatal Hernia and Chronic Digestive Symptoms

Structural, breathing, posture and nervous system factors may drive hiatal hernia and chronic reflux beyond medication alone. ROCKVILLE CENTRE, NY, UNITED STATES, December 26, 2025 / EINPresswire.com / -- Hiatal hernia and chronic digestive discomfort affect a substantial portion of the adult population in the United States. Clinical research indicates that hiatal hernias are present in approximately 20 percent of adults and are identified in nearly 30 percent of individuals undergoing upper endoscopy. Digestive conditions such as reflux, gastroesophageal reflux disease, and chronic heartburn are estimated to affect between 18 and 28 percent of U.S. adults. Despite the prevalence of these symptoms, many individuals remain unaware of the structural and neurological factors that may contribute to persistent discomfort. How Hiatal Hernia Impacts the Body A hiatal hernia occurs when part of the stomach shifts upward through the diaphragm. This displacement can interfere with normal pressure regulation beneath the sternum and alter breathing mechanics. Individuals may experience symptoms such as heartburn, reflux, chest tightness, post-meal discomfort, shallow breathing, or a persistent sensation of pressure in the upper abdomen. Chronic stress patterns, restricted breathing, and postural strain may further limit diaphragm mobility, increasing mechanical stress on digestive structures. Medication Reliance and Unresolved Symptoms Many individuals experiencing reflux or chronic heartburn and are prescribed proton pump inhibitors such as Nexium or Prilosec or rely on antacids like Tums for symptom management. While these medications may offer temporary relief, prolonged reliance without addressing contributing mechanical or neurological factors often results in incomplete symptom resolution. Patients frequently report undergoing upper endoscopy procedures that confirm irritation or inflammation, yet treatment recommendations often remain limited to medication management rather than exploring physical contributors. Long-Term Considerations and Potential Complications Chronic reflux and prolonged irritation of the esophagus have been associated with conditions such as Barrett’s esophagus. This condition involves abnormal cellular changes and has been linked to an increased risk of esophageal cancer. Health professionals emphasize that unresolved irritation over time may increase the likelihood of long-term complications. Improving awareness of contributing factors may help reduce unnecessary prolonged discomfort and associated health risks. Structural and Neurological Influences on Digestive Function From a structural perspective, diaphragm mobility, spinal alignment, breathing patterns, and nervous system regulation all influence digestive function. When the diaphragm becomes overly tense or restricted, stomach position and pressure balance may be disrupted, contributing to ongoing symptoms. Some clinical discussions include supportive modalities such as cold laser therapy, chiropractic adjustments, manual viscerialmanipulation and breathwork techniques as part of broader efforts to calm irritated tissue and support neuromuscular balance. These approaches are generally viewed as complementary within a wider focus on function and mobility. Community Awareness and Clinical Perspective Dr. John Gehnrich, a chiropractor with more than 25 years in practice since 2000, specializes in working with individuals experiencing chronic digestive symptoms associated with hiatal hernia, reflux, GERD, and persistent heartburn. Through years of clinical observation and customizing solutions to this chronic disorder plaguing so many of his patients, he has noted that many people arrive after long periods of symptom management without clear explanations for why discomfort continues. Dr. Gehnrich’s work focuses on identifying the underlying mechanical and neurological contributors that are often overlooked, including diaphragm restriction, postural strain, structural misalignment, altered breathing patterns, and nervous system imbalance. He emphasizes that these factors may play a significant role in digestive function and symptom persistence and has been a big part of his success with these patients over the years In his experience, many individuals feel frustrated after relying on medication alone or undergoing diagnostic procedures that confirm irritation without addressing why the condition developed or continues. By emphasizing education and awareness, Dr. Gehnrich aims to help individuals better understand how daily habits, stress patterns, posture, chiropractic adjustments, and breathing mechanics may influence long-term digestive health. Education and Prevention Through Awareness Health professionals note that improving public understanding of structural and neurological contributors to digestive symptoms may help individuals make more informed decisions about their care. Addressing underlying contributors rather than relying solely on long-term symptom suppression may support improved comfort and help reduce the progression of chronic digestive conditions. Reference Data and Sources Hiatal hernia prevalence https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/books/NBK562200/ Hiatal hernia findings during upper endoscopy https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/20381490/ GERD prevalence in the United States https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/23907619/ Proton pump inhibitor safety and long-term use https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication Barrett’s esophagus and cancer risk https://www-niddk-nih-gov.libproxy1.nus.edu.sg/health-information/digestive-diseases/barretts-esophagus Diaphragm function and breathing mechanics https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/29580445/ Contact Info - Rhino Chiropractic 14 Glen Cove Rd Roslyn Heights, NY 11577 516) 536-6000 www.rhinochiropractic.com Dr. John Gehnrich Rhino Chiropractic & Holistic Wellness Center +1 516-536-6000 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 May 2025

·pharma.economictimes.indiatimes.com

Many MSME pharma firms making substandard drugs, CDSCO data shows

New Delhi: Many pharmaceutical companies in the micro, small and medium enterprise (MSME) sector are manufacturing substandard drugs , according to the data by India's drug regulator, the Central Drugs Standard Control Organisation ( CDSCO ). According to the data for April, most of these companies are making drugs that failed safety standards and have been found to be sub- standard quality. As part of the continuous regulatory surveillance , drug samples are picked from sales and distribution points and analysed at various government run laboratories. According to the drug regulatory authority, in April about 60 samples failed to meet the quality standards and have been declared as Not of Standard Quality (NSQ) Drugs . Samples which failed tests are carboxymethylcellulose sodium eye drops, an eye lubricant, also known as artificial tears, bupivacaine hydrochloride injection, a local anaesthetic, calcium carbonate and vitamin D3 tablets, among others. Interestingly, they have been manufactured at lesser known pharma companies like Gidsha Pharmaceuticals in Gujarat, Martin and Brown Biosciences in Solan, Himachal Pradesh, Sai Parenterals in Hyderabad, Nestor Pharmaceuticals, Faridabad, among others. These companies could not be contacted immediately. "This has been the trend for some time now. Most of these MSME are found to be manufacturing drugs which are not of standard quality. That is the reason the health ministry came out with a notification which outlines standards for the pharma companies," said a person with knowledge of the matter. Earlier in 2023, over 65 per cent of MSME enterprises were found to be manufacturing drugs that were not of standard quality (NSQ) during risk-based inspections (RBI) of pharma companies. "Of the total MSME units inspected, 30 per cent were issued stop production orders (SPO), while samples of 68% MSME companies have failed. This is alarming," the person said. The CDSCO and state drug inspectors have been conducting these inspections as part of a massive nationwide crackdown on spurious and substandard medicines. This followed a controversy over alleged Made-in-India cough syrups being responsible for the deaths of children in The Gambia. The CDSCO has found that these companies have issues related to infrastructure, quality management systems and product manufacturing process knowledge. "There has been a strong correlation between NSQ and the condition of manufacturing set up. Monthly NSQ data shows repeat failures for a company with the same product with multiple companies month on month," another person said. India's drug regulator had earlier pointed to an urgent need to review the current GMP regulations and Quality Management Systems being followed by pharmaceutical companies during the RBI. By Teena Thacker ,

31 Dec 2024

·pharma.economictimes.indiatimes.com

Six common medications, including antibiotics and allergy drugs, fail quality tests

Jaipur: The health department released a list of six drugs on Monday that failed quality tests and are being sold in the market. These include commonly used antibiotics such as amoxicillin and clavulanate potassium, anti-allergic medicines like levocetirizine hydrochloride and montelukast, the gastro-resistant drug pantoprazole, and cefpodoxime, which is an antibiotic drug. These drugs failed the quality test as they did not contain any of the promised medicinal content. The drugs were manufactured in Bengaluru, Punjab, Sikkim, Mohali, and Himachal Pradesh. A sample of the medicine Pregabalin, which is in a class of medications called anticonvulsants, failed the quality test as it was found to have nil content of pregabalin. The drug was manufactured by a company in Mohali. A health department official said that directions have been issued to drug control officers in districts to remain alert and take necessary action. They have been directed to collect samples of other medicines manufactured by the companies whose samples failed the quality test. The samples of amoxicillin and clavulanate potassium manufactured by a Bengaluru-based firm failed as they contained none of the promised drugs. Earlier, a report was issued by the health department in which samples of drugs in combination with nimesulide and paracetamol (pain relief), pheniramine maleate injection (to treat symptoms of allergic conditions), a combination of calcium carbonate and vitamin D3 suspension (dietary supplement for people who have bone problems or low calcium and vitamin D levels), a combination of telmisartan, amlodipine, and hydrochlorothiazide (to treat high blood pressure), a combination of telmisartan and amlodipine (for high blood pressure), a combination of levocetirizine dihydrochloride and montelukast (relieves sneezing and runny nose due to allergies), heparin sodium injection (anticoagulant), and an injection of sulphamethoxazole and trimethoprim (treats infections caused by bacteria) failed quality tests. These drugs were manufactured in Baddi, Sirmour and Solan (Himachal Pradesh), Vadodara (Gujarat), Roorkee (Uttarakhand), and Digiana (Jammu).

100 Deals associated with Calcium carbonate

External Link

KEGG	Wiki	ATC	Drug Bank
D00932	Calcium carbonate	A12AA04 A02AC01	DB06724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperphosphatemia	Japan	Pfizer Japan, Inc.	16 Jun 1999
Hyperphosphatemia	Japan	Mylan Seiyaku Ltd.	16 Jun 1999
Osteoporosis	China	Haleon (Suzhou) Pharmaceutical Co. Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal Reflux	Phase 2	Japan	Otsuka Pharmaceutical Co., Ltd.	31 Oct 2017
Hyperchlorhydria	Phase 2	Japan	Otsuka Pharmaceutical Co., Ltd.	01 Aug 2014
Castration-Resistant Prostatic Cancer	Phase 1	Israel	Amorphical Ltd.	01 Jun 2022
Advanced Malignant Solid Neoplasm	Phase 1	Israel	Amorphical Ltd.	18 Jul 2018
Bone metastases	Phase 1	Israel	Amorphical Ltd.	18 Jul 2018
Liver metastases	Phase 1	Israel	Amorphical Ltd.	18 Jul 2018
Adrenocortical Carcinoma	Phase 1	Israel	Amorphical Ltd.	25 Jun 2017
Secondary malignant neoplasm of lung	Phase 1	Israel	Amorphical Ltd.	25 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECCO2026	Phase 2	Crohn Disease	23	Amorphous Calcium Carbonate (ACC) (moderate-to-severe Crohn’s disease)	fdevfihiwg(tjsqnjskip) = zbzqupvsnq xodhbbwsoc (imphhpdkdg, 33.0) View more	Positive	18 Feb 2026
				Placebo (moderate-to-severe Crohn’s disease)	fdevfihiwg(tjsqnjskip) = vbascnqoje xodhbbwsoc (imphhpdkdg, 33.0) View more
NCT02916862 (MetA-Bone, CTgov)	Phase 2	Osteoporosis	177	Soluble Corn Fiber+calcium carbonate (Soluble Corn Fiber (SCF) + Calcium)	ynqmikuuvn(otgqzvodjf) = msagjihonz zmmgeahkvs (wruwasmmhg, 11.8) View more	-	29 Oct 2025
				Soluble Corn Fiber (SCF) without Calcium (Soluble Corn Fiber (SCF) Without Calcium)	ynqmikuuvn(otgqzvodjf) = vrtmyblioz zmmgeahkvs (wruwasmmhg, 10.5) View more
NCT02186600 (HOPS, CTgov)	Phase 3	Osteoporosis	276	Calcium Carbonate+Vitamin D3 (Control)	tuvsycewpb(dkqstjcznl) = heglqjncxw rbcubvszar (lcpwainkiq, 334.7) View more	-	27 Jun 2023
				Risedronate+Calcium Carbonate+Vitamin D3 (Risedronate)	tuvsycewpb(dkqstjcznl) = kqtfbrjocd rbcubvszar (lcpwainkiq, 292.3) View more
NCT03089216 (CTgov)	Phase 4	Dentin Sensitivity	108	Combined Bleaching(2x20) (Combined Bleaching(2x20))	tvudkfwlnz(hprubdekng) = jxpshwlyxw mtkrlbjrui (qzphxtijdj, mvusyuwarc - rrwaglzlit) View more	-	05 Aug 2019
				Combined Bleaching (1x20) (Combined Bleaching(1x20))	tvudkfwlnz(hprubdekng) = rqnpbshokt mtkrlbjrui (qzphxtijdj, kizcgwzgxb - cpvockqwin) View more
NCT00416715 (CTgov)	Phase 2	Breast cancer recurrent \| Arthralgia \| Musculoskeletal Abnormalities ... View more	100	vitamin D (Baseline)	prfmwehoec = nvmtouqaka swxnleynhy (sqostvoups, dtzxvdrlpn - xabaeenzsf) View more	-	11 Jul 2017
				Vitamin D (Post Vitamin D Repletion (1 Month))	prfmwehoec = klukavqfvl swxnleynhy (sqostvoups, afatbqpqrk - fqdqmrglij) View more
NCT00620113 (0822-022 \| MK-0822-022, CTgov)	Phase 2	Osteoporosis, Postmenopausal	287	Placebo+Calcium carbonate+Vitamin D3 (Placebo)	fshvsgnpby(fyesvekwyk) = afklukaqfq cwqihbnrvb (zmgndcmxyq, vurszmlqzr - efqnabuqfh) View more	-	13 Mar 2017
				Odanacatib+Calcium carbonate+Vitamin D3 (Odanacatib 10 mg)	fshvsgnpby(fyesvekwyk) = jtqtcahyhr cwqihbnrvb (zmgndcmxyq, pbvwcedtkg - dbwkpuhwam) View more
NCT00073073 (CTgov)	Phase 2	Noninfiltrating Intraductal Carcinoma \| Invasive Mammary Carcinoma	46	Vitamin D+Exemestane+Calcium carbonate	apvnlohzdf(tohyofowwi) = fpglolzvxr peuzmhiodh (lwwhklhsfo, xdkzqjgqma - biipjnxtig) View more	-	17 May 2016
NCT00001304 (CTgov)	Phase 2	Hypoparathyroidism	27	Synthetic Human Parathyroid Hormone 1-34 (PTH 1-34)	lgtmfrghyg(xgjsplvkay) = mprquijmgn tjtclixdfv (gexnhmjavv, 0.02) View more	-	15 Dec 2015
				calcitriol+Calcium carbonate (Calcitriol & Calcium)	prockqckpy(vdopnmuvqh) = vtgjhycxkq wcapjemgaj (udmjytmqqe, nrxiedisjd - qanulglyer) View more
NCT01578200 (LANDMARK, ASN2015)	Phase 3	Hodgkin's Lymphoma intact parathyroid hormone (iPTH)	2,309	Lanthanum Carbonate (LC)	ialbgcjrok(smbxeeqyjj) = rxvhcghpzf rnuzwvgusr (cxgyhfvicq ) View more	Positive	03 Nov 2015
				Calcium Carbonate (CC)	ialbgcjrok(smbxeeqyjj) = jjazunnnyi rnuzwvgusr (cxgyhfvicq ) View more
ERA2015	Phase 4	Hyperphosphatemia	102	Calcium Carbonate Emulsion (CCE)	tqfdhgtjsj(zmjjeswumg) = CCE seems to show less forgetfulness in taking medication euffmrmqnc (bbiaxsrztd ) View more	Positive	21 May 2015
				Calcium Carbonate Tablets (CCT)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis